公开(公告)号：US20170029412A1

公开(公告)日：2017-02-02

申请号：US15292200

申请日：2016-10-13

申请人： GlaxoSmithKline Intellectual Property (No.2) Limited

发明人： Charles William BLACKLEDGE, JR. ,  Joelle Lorraine BURGESS ,  Neil W. JOHNSON ,  Jiri KASPAREC ,  Steven David KNIGHT ,  Louis V. LaFRANCE, III ,  Juan I. LUENGO ,  William Henry MILLER ,  Kenneth Allen NEWLANDER ,  Stuart Paul ROMERIL ,  Mark SCHULZ ,  Dai-Shi SU ,  Xinrong TIAN

IPC分类号： C07D409/14 ,  C07D409/06 ,  C07D405/14 ,  C07D409/12 ,  C07D401/12

CPC分类号： C07D409/14 ,  C07D401/12 ,  C07D403/12 ,  C07D405/14 ,  C07D409/06 ,  C07D409/12 ,  C07D413/14

摘要： This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

摘要翻译： 本发明涉及式（I）的新化合物，其为Zeste同系物2（EZH2）的增效剂的抑制剂，含有它们的药物组合物，其制备方法及其在治疗癌症中的用途。

公开(公告)号：US20160102083A1

公开(公告)日：2016-04-14

申请号：US14787866

申请日：2014-04-25

申请人： GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED

发明人： Charles William BLACKLEDGE, JR. ,  Joelle Lorraine BURGESS ,  Neil W. JOHNSON ,  Jiri KASPAREC ,  Steven David KNIGHT ,  Louis V. LaFRANCE, III ,  Juan I. LUENGO ,  William Henry MILLER ,  Kenneth Allen NEWLANDER ,  Stuart Paul ROMERIL ,  Mark SCHULZ ,  Dai-Shi SU ,  Xinrong TIAN

IPC分类号： C07D409/14 ,  C07D403/12 ,  C07D405/14 ,  C07D409/12

CPC分类号： C07D409/14 ,  C07D401/12 ,  C07D403/12 ,  C07D405/14 ,  C07D409/06 ,  C07D409/12 ,  C07D413/14

摘要： This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.